These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 17496526)

  • 1. Reducing the risks of cardiovascular disease in liver allograft recipients.
    Mells G; Neuberger J
    Transplantation; 2007 May; 83(9):1141-50. PubMed ID: 17496526
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The 2005 Canadian Hypertension Education Program recommendations for the management of hypertension: part II - therapy.
    Khan NA; McAlister FA; Lewanczuk RZ; Touyz RM; Padwal R; Rabkin SW; Leiter LA; Lebel M; Herbert C; Schiffrin EL; Herman RJ; Hamet P; Fodor G; Carruthers G; Culleton B; DeChamplain J; Pylypchuk G; Logan AG; Gledhill N; Petrella R; Campbell NR; Arnold M; Moe G; Hill MD; Jones C; Larochelle P; Ogilvie RI; Tobe S; Houlden R; Burgess E; Feldman RD;
    Can J Cardiol; 2005 Jun; 21(8):657-72. PubMed ID: 16003449
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Arterial hypertension and dyslipidemia in patients with chronic kidney disease (CKD). Anti-platelet aggregation. Goal oriented treatment].
    Cases Amenós A; Goicoechea Diezhandiño M; de Alvaro Moreno F
    Nefrologia; 2008; 28 Suppl 3():39-48. PubMed ID: 19018737
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metabolic syndrome: treatment of hypertensive patients.
    Israili ZH; Lyoussi B; Hernández-Hernández R; Velasco M
    Am J Ther; 2007; 14(4):386-402. PubMed ID: 17667215
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cardiac allograft vasculopathy after heart transplantation: risk factors and management.
    Valantine H
    J Heart Lung Transplant; 2004 May; 23(5 Suppl):S187-93. PubMed ID: 15093804
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
    Weir MR
    Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Cardiovascular disease after renal transplantation].
    Montanaro D; Gropuzzo M; Tulissi P; Boscutti G; Risaliti A; Baccarani U; Adani GL; Sainz M; Bresadola F; Mioni G
    G Ital Nefrol; 2004; 21 Suppl 26():S53-66. PubMed ID: 15732047
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rationale, design and patient baseline characteristics of OlmeSartan and calcium antagonists randomized (OSCAR) study: a study comparing the incidence of cardiovascular events between high-dose angiotensin II receptor blocker (ARB) monotherapy and combination therapy of ARB with calcium channel blocker in Japanese elderly high-risk hypertensive patients (ClinicalTrials. gov no. NCT00134160).
    Ogawa H; Kim-Mitsuyama S; Jinnouchi T; Matsui K; Arakawa K
    Hypertens Res; 2009 Jul; 32(7):575-80. PubMed ID: 19444280
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Antihypertensive agents and the risk of new onset diabetes mellitus].
    Kuzmanić D; Laganović M; Dika Z; Kos J; Pećin I
    Lijec Vjesn; 2006; 128(11-12):336-41. PubMed ID: 17212194
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recent update in the management of hypertension.
    Lim S
    Acta Med Indones; 2007; 39(4):186-91. PubMed ID: 18380058
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The combination of an ACE inhibitor and a calcium channel blocker is an optimal combination for the treatment of hypertension].
    Widimský J
    Vnitr Lek; 2009 Feb; 55(2):123-30. PubMed ID: 19348394
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Arterial hypertension in renal transplant recipients].
    Basić-Jukić N; Jurić I; Kes P; Bubić-Filipi L; Brunetta B; Pasini J
    Acta Med Croatica; 2007 Apr; 61(2):171-6. PubMed ID: 17585473
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Does the rennin inhibitor aliskiren offer promising novel opportunities in the treatment of cardiovascular diseases?].
    Horký K
    Vnitr Lek; 2007 Apr; 53(4):364-70. PubMed ID: 17578167
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Management of mixed dyslipidemia in patients with or at risk for cardiovascular disease: a role for combination fibrate therapy.
    Fazio S
    Clin Ther; 2008 Feb; 30(2):294-306. PubMed ID: 18343268
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The development of new-onset type 2 diabetes associated with choosing a calcium channel blocker compared to a diuretic or beta-blocker.
    Kuti EL; Baker WL; White CM
    Curr Med Res Opin; 2007 Jun; 23(6):1239-44. PubMed ID: 17559720
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of recent fixed-dose combination therapies in the management of hypertension.
    Khanna A; Lefkowitz L; White WB
    Curr Opin Nephrol Hypertens; 2008 Sep; 17(5):477-83. PubMed ID: 18695388
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treating the metabolic syndrome.
    Bianchi C; Penno G; Romero F; Del Prato S; Miccoli R
    Expert Rev Cardiovasc Ther; 2007 May; 5(3):491-506. PubMed ID: 17489673
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Management of cardiovascular risk with RAS inhibitor/CCB combination therapy.
    Dahlöf B
    J Hum Hypertens; 2009 Feb; 23(2):77-85. PubMed ID: 18685606
    [TBL] [Abstract][Full Text] [Related]  

  • 19. When hypertension and diabetes coexist: strategies for cardiorenal protection.
    Weber MA
    Postgrad Med; 2000 Oct; 108(5 Suppl):12-8. PubMed ID: 19667536
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting mechanisms of hypertensive vascular disease with dual calcium channel and renin-angiotensin system blockade.
    Weir MR
    J Hum Hypertens; 2007 Oct; 21(10):770-9. PubMed ID: 17597800
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.